Posted on 19 November 2008
The randomized placebo-controlled trial of 3,069 people aged 75 or older from five U.S. cities followed participants with dementia assessments for an average of six years, to determine whether a daily dose of ginkgo could delay or prevent dementia.
Popularity: 7% [?]
Posted on 19 November 2008
The financial crisis may have a silver lining for Big Pharma. Licensing deals struck by drugmakers with smaller biotechs could really take off.
With credit tightening and the market values of some smaller companies taking a beating, the terms for Big Pharma may get a whole lot more attractive, the Boston Consulting Group says in a [...]
Popularity: 5% [?]
Posted on 19 November 2008
Company’s MPACs for the Treatment of Alzheimer’s Disease Shown to Prevent Neural Cell Death and the Production of Amyloid-Beta Protein
MELBOURNE, Australia — Prana Biotechnology Limited (Nasdaq: PRAN / ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced that a recent independent study conducted by Massachusetts General [...]
Popularity: 6% [?]
Posted on 19 November 2008
Eli Lilly launched US legal proceedings against Novartis’ Sandoz unit, Wockhardt, Impax Laboratories and Cobalt Laboratories to prevent the drugmakers from manufacturing generic versions of its antidepressant Cymbalta (duloxetine).
The Indianapolis-based company alleged that the generic firms have filed documents with the FDA seeking permission to market the drug before the patent expires in June 2013. [...]
Popularity: 5% [?]
Posted on 19 November 2008
Findings from a meta-analysis published in JAMA suggest that patients with cancer who were treated with Roche’s and Genentech’s Avastin (bevacizumab) were at a significantly increased risk of developing venous thromboembolism (VTE), compared with those who do not receive the drug.
Researchers analysed data from 15 randomised trials involving a total of 7956 patients with a [...]
Popularity: 5% [?]
Business of Health
Posted on 19 November 2008
The financial crisis may have a silver lining for Big Pharma. Licensing deals struck by drugmakers with smaller biotechs could really take off.
With credit tightening and the market values of some smaller companies taking a beating, the terms for Big Pharma may get a whole lot more attractive, the Boston Consulting Group says in a [...]
Popularity: 5% [?]
Drug Development
Posted on 14 November 2008
As part of the study, researchers randomly assigned 4065 males between the ages of 16 and 26 to receive three injections of either Gardasil or placebo over a six-month period.
Popularity: unranked [?]
Neurological Disorders
Posted on 18 November 2008
Scientists have identified a molecule which could be key to understanding the cause of motor neurone disease (MND) and other neurodegenerative disorders.
The Proceedings of the National Academy of Sciences study raises the hope of new treatments being developed.
The London-based team showed the molecule, Wnt3, plays a key role in establishing connections between nerve cells and [...]
Popularity: 11% [?]
News Wire
Posted on 18 November 2008
Cephalon has already taken heat for off-label promotion of its narcolepsy drug Provigil. Now, facing the prospect of generic competition to Provigil in 2012, the company is dramatically hiking Provigil’s price.
The drug is 28% more expensive than it was in March and 74% higher than four years ago, according to DestinationRx.
It would seem a price [...]
Popularity: 13% [?]
Pharmaceutical Industry
Posted on 17 November 2008
In safety review documents posted to the FDA website, agency staff recommended that Eli Lilly’s antipsychotic Zyprexa (olanzapine) and Novartis’ antifungal medication Lamisil (terbinafine) should be monitored for potential risks of adverse events in the paediatric population.
Regarding Zyprexa, the agency staff noted that “no new safety signals emerged as part of this review; however, it [...]
Popularity: unranked [?]
